TARA
NASDAQProtara Therapeutics Inc.
News · 26 weeks320%
2026-04-192026-10-11
Mix790d
- Other4(57%)
- SEC Filings3(43%)
Latest news
25 items- PRProtara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral SupportCompany remains on track to report interim results from Phase 2b cohort in 4Q 2026 NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has completed enrollment of the Phase 2b, open-label dose confirmation phase of the THRIVE-3 clinical trial evaluating IV Choline Chloride in patients with intestinal failure who are dependent on parenteral support (PS). The dose confirmation phase of the trial includes 24 patients. "We are excited about our progress in the registrational THRIVE-3 trial, which brings us one step
- PRProtara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceNEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transforma
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
- SECSEC Form S-8 filed by Protara Therapeutics Inc.S-8 - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECSEC Form 10-Q filed by Protara Therapeutics Inc.10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateExpect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary (Ta/T1) patients across BCG exposures Expect to provide an update and complete enrollment of the STARBORN-1 trial in LMs in 4Q 2026; expect to submit a Biologics License Application for TARA-002 in LMs in 2H 2027 On track to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 4Q 2026 Cash, cash equivalents an
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
- INSIDERCEO and President Shefferman Jesse gifted 30,000 shares, exercised 215,687 shares at a strike of $1.91 and sold $882,160 worth of shares (215,687 units at $4.09), decreasing direct ownership by 4% to 691,832 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- INSIDERSEC Form 4 filed by Director Levy Richard S4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Solomon Michael Edward4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Cynthia4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Sargen Gregory4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Huang Jane4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Flannelly Barry P4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Garceau Roger4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Director Beshar Luke M4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- INSIDERChief Commercial Officer Conkling William covered exercise/tax liability with 6,008 shares, decreasing direct ownership by 8% to 69,992 units (SEC Form 4) to satisfy withholding tax4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- SECSEC Form 424B5 filed by Protara Therapeutics Inc.424B5 - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECSEC Form EFFECT filed by Protara Therapeutics Inc.EFFECT - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHANEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About Protara Therapeutics, Inc. Protara is a clinic
- PRProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and regulatory path for TARA-002 and a review of cl
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
TARA FAQ
7 questionsWhat does Protara Therapeutics Inc. do?
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May...Where does TARA stock trade?
Protara Therapeutics Inc. (TARA) is listed on NASDAQ.What sector and industry is TARA in?
Protara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Protara Therapeutics Inc. go public?
Protara Therapeutics Inc. (TARA) completed its IPO in 2014.What are analysts saying about TARA?
Protara Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $2700.00 price target on 2026-03-04. Recent price targets range from $1200.00 to $3400.00.What companies are similar to TARA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare TARA side-by-side with any of them on Quantisnow.How can I track TARA on Quantisnow?
Quantisnow aggregates Protara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARA to receive live email and push alerts on every new disclosure.